SE449360B - Alkylendiaminderivat, forfarande for dess framstellning samt farmaceutisk komposition innehallande denna - Google Patents
Alkylendiaminderivat, forfarande for dess framstellning samt farmaceutisk komposition innehallande dennaInfo
- Publication number
- SE449360B SE449360B SE7900987A SE7900987A SE449360B SE 449360 B SE449360 B SE 449360B SE 7900987 A SE7900987 A SE 7900987A SE 7900987 A SE7900987 A SE 7900987A SE 449360 B SE449360 B SE 449360B
- Authority
- SE
- Sweden
- Prior art keywords
- compound
- iii
- methyl
- amine
- amino
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 42
- -1 4-amino-6,7-dimethoxy-2-quinazolyl Chemical group 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 10
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 10
- 229960001289 prazosin Drugs 0.000 description 10
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 230000008602 contraction Effects 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 6
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 6
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241000283986 Lepus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229960001789 papaverine Drugs 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 210000001147 pulmonary artery Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- HWIIAAVGRHKSOJ-UHFFFAOYSA-N 2-chloro-6,7-dimethoxyquinazolin-4-amine Chemical compound ClC1=NC(N)=C2C=C(OC)C(OC)=CC2=N1 HWIIAAVGRHKSOJ-UHFFFAOYSA-N 0.000 description 1
- UNIJBMUBHBAUET-UHFFFAOYSA-N 3-(methylamino)propanenitrile Chemical compound CNCCC#N UNIJBMUBHBAUET-UHFFFAOYSA-N 0.000 description 1
- FYMQPWWNOCENRN-UHFFFAOYSA-N 6,7-dimethoxyquinazoline Chemical compound N1=CN=C2C=C(OC)C(OC)=CC2=C1 FYMQPWWNOCENRN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- INVHITWXZHGYEG-UHFFFAOYSA-N n-(2-cyanoethyl)-n-methyloxolane-2-carboxamide Chemical compound N#CCCN(C)C(=O)C1CCCO1 INVHITWXZHGYEG-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7803175A FR2421888A1 (fr) | 1978-02-06 | 1978-02-06 | Amides d'alkylene-diamines et leur application en therapeutique |
| FR7836819A FR2445323A2 (fr) | 1978-02-06 | 1978-12-29 | Amides d'alkylenediamines et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7900987L SE7900987L (sv) | 1979-08-07 |
| SE449360B true SE449360B (sv) | 1987-04-27 |
Family
ID=26220430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7900987A SE449360B (sv) | 1978-02-06 | 1979-02-05 | Alkylendiaminderivat, forfarande for dess framstellning samt farmaceutisk komposition innehallande denna |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4315007A (de) |
| JP (1) | JPS6023114B2 (de) |
| AT (1) | AT365176B (de) |
| AU (1) | AU521524B2 (de) |
| BE (1) | BE873909A (de) |
| CA (1) | CA1102330A (de) |
| CH (1) | CH637122A5 (de) |
| DE (1) | DE2904445C2 (de) |
| DK (1) | DK159316C (de) |
| ES (1) | ES477457A1 (de) |
| FI (1) | FI66861C (de) |
| FR (2) | FR2421888A1 (de) |
| GB (1) | GB2013679B (de) |
| GR (1) | GR66846B (de) |
| IE (1) | IE47812B1 (de) |
| IL (1) | IL56578A (de) |
| IT (1) | IT1192347B (de) |
| LU (1) | LU80880A1 (de) |
| NL (2) | NL181482C (de) |
| NO (1) | NO151463C (de) |
| NZ (1) | NZ189553A (de) |
| PT (1) | PT69178A (de) |
| SE (1) | SE449360B (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2466462A2 (fr) * | 1978-02-06 | 1981-04-10 | Synthelabo | Derives d'alkylenediamines, leur preparation et leur application en therapeutique |
| EP0105838B1 (de) * | 1982-09-30 | 1989-06-21 | William John Louis | 3-Aminopropoxyphenyl-Derivate, ihre Herstellung und diese enthaltende pharmazeutische Mittel |
| FR2570275B1 (fr) * | 1984-09-14 | 1986-11-21 | Synthelabo | Compositions pharmaceutiques a base de diltiazem et d'alfusozine |
| FR2577804B1 (fr) * | 1985-02-26 | 1987-03-27 | Synthelabo | Compositions pharmaceutiques a base de verapamil et d'alfuzosine |
| FR2577803B1 (fr) * | 1985-02-26 | 1987-04-03 | Synthelabo | Compositions pharmaceutiques a base de nifedipine et d'alfuzosine |
| EP0189336A1 (de) * | 1985-01-18 | 1986-07-30 | Synthelabo | Pharmazeutische Zusammensetzungen mit Gehalt an einem alpha-Blocker und an einem Calcium-Antagonisten |
| FR2582513B1 (fr) * | 1985-05-28 | 1988-08-05 | Synthelabo | Compositions pharmaceutiques contenant de l'alfuzosine |
| LU86672A1 (fr) * | 1986-11-19 | 1988-06-13 | Oreal | Composition pour induire et stimuler la croissance des cheveux et diminuer la chute a base de derives d'alkylene diamino quinazoline |
| YU70890A (en) * | 1989-04-21 | 1992-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for obtaining quinazoline derivatives |
| NZ241979A (en) * | 1991-03-20 | 1996-01-26 | Merck & Co Inc | Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker |
| FR2694495B1 (fr) * | 1992-08-05 | 1994-09-23 | Synthelabo | Préparation pharmaceutique transdermique contenant de l'alfuzosine. |
| JPH07206857A (ja) * | 1993-12-28 | 1995-08-08 | Synthelabo Sa | アルフゾシン塩酸塩の二水和物 |
| FR2717388B1 (fr) * | 1994-03-21 | 1996-11-22 | Synthelabo | Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine. |
| US6313294B1 (en) | 1998-02-04 | 2001-11-06 | Development Center For Biotechnology | Process for preparing amides |
| EP1891954A3 (de) | 1998-09-30 | 2009-01-14 | Takeda Pharmaceutical Company Limited | Wirkstoffe zur Verbesserung der Exkretionskraft der Harnblase |
| AU2001240150A1 (en) * | 2000-03-13 | 2001-09-24 | Chemrx Advanced Technologies, Inc. | Quinazoline synthesis |
| US20020065286A1 (en) * | 2000-08-21 | 2002-05-30 | Davies Michael John | Treatment of wounds |
| US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| US20030229001A1 (en) * | 2002-01-31 | 2003-12-11 | Pfizer Inc. | Treatment of male sexual dysfunction |
| GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
| US7323462B2 (en) * | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
| ES2341240T3 (es) | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| PA8597401A1 (es) * | 2003-03-14 | 2005-05-24 | Pfizer | Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep |
| US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| US7291640B2 (en) * | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
| US20050267096A1 (en) * | 2004-05-26 | 2005-12-01 | Pfizer Inc | New indazole and indolone derivatives and their use pharmaceuticals |
| US20050288270A1 (en) * | 2004-05-27 | 2005-12-29 | Pfizer Inc | New aminopyridine derivatives and their use as pharmaceuticals |
| EP1789412B1 (de) * | 2004-09-16 | 2008-05-07 | Hetero Drugs Limited | Kristalline alfuzosinbase |
| JP2008533193A (ja) * | 2005-03-21 | 2008-08-21 | ファイザー・リミテッド | オキシトシン拮抗薬としての置換トリアゾール誘導体 |
| WO2006100557A1 (en) * | 2005-03-21 | 2006-09-28 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| CA2618103A1 (en) * | 2005-08-10 | 2007-02-15 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| US20070066824A1 (en) * | 2005-09-22 | 2007-03-22 | Anumula Raghupathi R | Preparation of alfuzosin |
| US20070105880A1 (en) * | 2005-11-08 | 2007-05-10 | Torrent Pharmaceuticals Limited | Process for the preparation of alfuzosin |
| US20090069562A1 (en) * | 2005-12-26 | 2009-03-12 | Joseph Prabahar Koilpillai | Process for the preparation of alfuzosin |
| CN100564376C (zh) * | 2006-09-19 | 2009-12-02 | 浙江华纳药业有限公司 | 阿夫唑嗪的制备方法 |
| CN101190890B (zh) * | 2006-11-30 | 2011-04-27 | 江苏豪森药业股份有限公司 | 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺 |
| US20080160081A1 (en) * | 2006-12-11 | 2008-07-03 | Mutual Pharmaceutical Company, Inc. | Alfuzosin formulations, methods of making, and methods of use |
| US20100092556A1 (en) * | 2006-12-11 | 2010-04-15 | Kristin Arnold | Alfuzosin formulations, methods of making, and methods of use |
| WO2008152514A2 (en) | 2007-05-04 | 2008-12-18 | Actavis Group Ptc Ehf | Process for the preparation of alfuzosin and salts thereof |
| WO2009001369A1 (en) * | 2007-06-22 | 2008-12-31 | Alembic Limited | An improved process for the preparation of alfuzosin hydrochloride |
| WO2009007987A1 (en) * | 2007-07-11 | 2009-01-15 | Alembic Limited | An improved process for the preparation of alfuzosin and its novel polymorph |
| US8716476B2 (en) * | 2007-08-02 | 2014-05-06 | Cipla Limited | Process for the preparation of alfuzosin hydrochloride |
| US20090076043A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched alfuzosin |
| WO2010083360A2 (en) * | 2009-01-16 | 2010-07-22 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations |
| CN107998090A (zh) * | 2017-12-30 | 2018-05-08 | 威海贯标信息科技有限公司 | 一种阿夫唑嗪片组合物 |
| CN113801069B (zh) * | 2020-06-15 | 2024-03-15 | 鲁南制药集团股份有限公司 | 一种盐酸阿夫唑嗪中间体化合物 |
| CN114573569B (zh) * | 2022-03-30 | 2023-07-04 | 邦恩泰(山东)生物医药科技集团股份有限公司 | 一种异喹啉类化合物的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635979A (en) * | 1969-09-29 | 1972-01-18 | Pfizer | Certain 6- and/or 7-alkoxy-substituted-2 4-bis(disubstituted amino) quinazolines |
| US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
| US4060615A (en) * | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
| FR2350101A1 (fr) * | 1976-05-07 | 1977-12-02 | Synthelabo | Nouvelles guanidines cyclisees |
| FR2362630A1 (fr) * | 1976-08-24 | 1978-03-24 | Synthelabo | Derives d'alkylenediamines |
| DK140695C (da) * | 1976-05-07 | 1980-05-12 | Synthelabo | Analogifremgangsmaade til fremstilling af 2,4-diamino-6,7-dimethoxyquinazolinderivater eller syreadditionssalte heraf |
| FR2389613A2 (en) * | 1977-05-05 | 1978-12-01 | Synthelabo | Antihypertensive 4-amino-6,7-di:methoxy-quinazolyl alkylene di:amine - prepd. from a 2-halo-quinazoline and an alkylene di:amine |
-
1978
- 1978-02-06 FR FR7803175A patent/FR2421888A1/fr active Granted
- 1978-12-29 FR FR7836819A patent/FR2445323A2/fr active Granted
-
1979
- 1979-02-02 DK DK046079A patent/DK159316C/da not_active IP Right Cessation
- 1979-02-02 NZ NZ189553A patent/NZ189553A/xx unknown
- 1979-02-02 AU AU43895/79A patent/AU521524B2/en not_active Expired
- 1979-02-02 BE BE0/193248A patent/BE873909A/xx not_active IP Right Cessation
- 1979-02-02 GR GR50581A patent/GR66846B/el unknown
- 1979-02-02 IL IL56578A patent/IL56578A/xx unknown
- 1979-02-05 ES ES477457A patent/ES477457A1/es not_active Expired
- 1979-02-05 NO NO790358A patent/NO151463C/no unknown
- 1979-02-05 CH CH112079A patent/CH637122A5/fr not_active IP Right Cessation
- 1979-02-05 CA CA320,864A patent/CA1102330A/en not_active Expired
- 1979-02-05 IE IE210/79A patent/IE47812B1/en not_active IP Right Cessation
- 1979-02-05 LU LU80880A patent/LU80880A1/fr unknown
- 1979-02-05 FI FI790369A patent/FI66861C/fi not_active IP Right Cessation
- 1979-02-05 IT IT19908/79A patent/IT1192347B/it active Protection Beyond IP Right Term
- 1979-02-05 JP JP54012737A patent/JPS6023114B2/ja not_active Expired
- 1979-02-05 PT PT7969178A patent/PT69178A/pt active IP Right Revival
- 1979-02-05 AT AT0084279A patent/AT365176B/de not_active IP Right Cessation
- 1979-02-05 SE SE7900987A patent/SE449360B/sv not_active IP Right Cessation
- 1979-02-06 NL NLAANVRAGE7900917,A patent/NL181482C/xx not_active IP Right Cessation
- 1979-02-06 DE DE2904445A patent/DE2904445C2/de not_active Expired
- 1979-02-06 GB GB79403279A patent/GB2013679B/en not_active Expired
- 1979-12-10 US US06/099,622 patent/US4315007A/en not_active Expired - Lifetime
-
1993
- 1993-05-28 NL NL930043C patent/NL930043I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE449360B (sv) | Alkylendiaminderivat, forfarande for dess framstellning samt farmaceutisk komposition innehallande denna | |
| US5618818A (en) | Muscarinic agonist compounds | |
| AU757290B2 (en) | Imidazolone anorectic agents: II. phenyl derivatives | |
| IE44613B1 (en) | 2-piperazinyl-6,7-dimethoxyquinazolines | |
| JPH05294935A (ja) | アミノピリジン系化合物 | |
| KR880001317B1 (ko) | 이미다졸릴페닐 아미딘 유도체의 제조방법 | |
| US4783530A (en) | 8-arylxanthines | |
| WO1999062892A1 (en) | Aminoazole compounds | |
| HU190639B (en) | Process for production of new aminoguanidin derivatives | |
| JPH02138266A (ja) | ６‐フェニル‐３‐（ピペラジニルアルキル）‐２，４（１ｈ，３ｈ）‐ピリミジンジオン誘導体 | |
| Stout et al. | Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 3. Modifications to the linkage region (region 3) | |
| HU176110B (en) | Process for producing thiourea- and guanidine derivatives | |
| US4318915A (en) | Substituted guandines and methods of preparation thereof | |
| US3728340A (en) | Piperazine derivatives and processes for their manufacture | |
| US4022798A (en) | 2-(5-Phenyl-2-furyl)imidazolines | |
| US3726902A (en) | Furfuryl amino-coumarins | |
| EP0185368B1 (de) | Aminobenzamide Derivate | |
| US3373163A (en) | N-methyl-piperazides of alicyclic and heterocyclic carboxylic acids | |
| FI89918C (fi) | Foerfarande foer framstaellning av ett terapeutiskt anvaendbart kristallint 2-(1-pentyl-3-guanidino)-4-(2-metyl-4-imidazolyl)tiazoldihydrokloridtrihydrat | |
| US3772280A (en) | Thiomorpholine-coumarin derivatives | |
| IL34741A (en) | Basically substituted 2,4-(1h,3h)-quinazolinedione derivatives,their preparation and pharmaceutical compositions containing them | |
| FI58125C (fi) | Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolin med blodtryckssaenkande vekan | |
| FI65428C (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefulla 2-fenylamino-imidazolin(2) derivat | |
| EP0083256A1 (de) | Benzamidderivate | |
| US3164585A (en) | Hydrazones of cyclichalovinylaldehydes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7900987-4 Format of ref document f/p: F |
|
| SPCF | Application for supplementary protection certificate filed |
Free format text: 9590002, 941219 |
|
| SPCG | Supplementary protection certificate granted |
Free format text: 9590002, 941219, EXPIRES: 20021111 |
|
| NUG | Patent has lapsed |
Ref document number: 7900987-4 Format of ref document f/p: F |